@article{soussain:hal-02182035,
TITLE = {Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network},
AUTHOR = {Soussain, C. and Choquet, S. and Blonski, M. and Leclercq, D. and Houillier, C. and Rezai, K. and Bijou, F. and Houot, R. and Boyle, E. and Gressin, R. and Nicolas-Virelizier, E. and Barrie, M. and Molu{\c c}on-Chabrot, C. and Lelez, M.L. and Clavert, A. and Coisy, S. and Leruez, S. and Touitou, V. and Cassoux, N. and Daniau, M. and Ertault de La Bretonni{\`e}re, M. and El Yamani, A. and Ghesqui{\`e}res, H. and Hoang-Xuan, K.},
URL = {https://univ-rennes.hal.science/hal-02182035},
JOURNAL = {European Journal of Cancer},
PUBLISHER = {Elsevier},
VOLUME = {117},
PAGES = {121-130},
YEAR = {2019},
MONTH = Aug, DOI = {10.1016/j.ejca.2019.05.024},
KEYWORDS = {Relapse ; Primary CNS lymphoma ; Primary vitreoretinal lymphoma ; Ibrutinib},
PDF = {https://univ-rennes.hal.science/hal-02182035/file/S0959804919303508.pdf},
HAL_ID = {hal-02182035},
HAL_VERSION = {v1},
}